hERG (Kv11.1) - HEK293 Recombinant Cell line

Catalog #
60619
$1,815 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant HEK293 cell line expressing human ERG potassium channel (ether-a-gogo-related gene, also known as KCNH2 or Kv11.1, accession number NM_000238).

This product has been cited 5 times.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
ERG, human ether-a-go-go-related gene, ether a go go ERG
Product Info
Storage and Usage
Citations5
Host Cell Line
HEK293
Species
Human
Supplied As
Each vial contains ~1.5 X 106 cells in 1 ml of 10% DMSO.
Materials Required But Not Supplied

Materails Required for Cell Culture

Name Ordering Information
Thaw Medium 1 BPS Bioscience #60187
Growth Medium 1B BPS Bioscience #79531
Biological Activity
The channel has been validated for activity using a fluorescence-based assay that uses thallium influx as a surrogate indicator of potassium ion channel activity coupled with a thallium-sensitive fluorescent dye.
Genbank #
NM_000238
UniProt #
Q12809
Mycoplasma Testing
The cell line has been screened using the PCR-based VenorGeM® Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Background

hERG (human ether-a-go-go-related gene) encodes the alpha subunit of a potassium ion channel, Kv11.1. It contains six transmembrane α-helices with a re-entrant “poreloop” between the fifth and the sixth transmembrane helices. This ion channel is best known for its contribution to the electrical activity of the heart that coordinates the heart's beating. When this channel's ability to conduct electrical current across the cell membrane is inhibited or compromised, either by application of drugs or by rare mutations, it can result in a potentially fatal disorder called long QT syndrome. A number of clinically successful drugs in the market exhibit the potential to inhibit hERG, and create a concomitant risk of sudden death as a side-effect, which has made hERG inhibition an important off-target that must be avoided during drug development.

References

1. Beacham, D.W. et al. (2010). J. Biomol. Screen. 15(4):441-446

2. Murphy, S.M. et al. (2006) J. Pharmacol. Toxicol. Methods. 54(1):42-55